Ovarian Cancer Cells Begin Adapting to Treatment Within Hours - and a Lung Cancer Drug Can Block Them

Drug resistance in cancer is usually described as something that accumulates. Tumors acquire mutations across treatment cycles until the therapy stops working. That framing assumes the problem takes time to develop. Preclinical research from Mayo Clinic suggests that in ovarian cancer, resistance may begin far earlier - within hours of a patient's first exposure to treatment - and that the molecular program cells activate at that point may be setting the stage for eventual treatment failure.

The finding, published by Mayo Clinic researchers, also identifies a potential strategy for blocking that early response. The drug is already approved - for a different cancer entirely.

PARP Inhibitors and the Resistance Problem

PARP inhibitors are a standard treatment for ovarian cancer, particularly in cases with deficient DNA repair mechanisms such as BRCA mutations. They work by blocking an enzyme cancer cells rely on to fix DNA damage, driving those cells toward death. For many patients, especially those with BRCA1 or BRCA2 mutations, PARP inhibitors have meaningfully extended survival. The persistent challenge is that many tumors eventually stop responding.

Most research on PARP inhibitor resistance has examined changes that develop over multiple treatment cycles - genetic mutations, altered pathway activity, restored DNA repair capacity. The Mayo team took an earlier vantage point: what is happening in the first hours after treatment begins?

They found that ovarian cancer cells rapidly activate a transcription factor called FRA1. Transcription factors control which genes are switched on or off, and FRA1 appears to activate a pro-survival program that allows cancer cells to begin adapting to treatment stress from the very start, well before resistance becomes clinically apparent.

"This work shows that drug resistance does not always emerge slowly over time - cancer cells can activate survival programs very early after treatment begins," said Arun Kanakkanthara, oncology investigator at Mayo Clinic and senior author of the study. "By targeting that early response, we may be able to improve how well existing therapies work and potentially delay or prevent resistance."

An Unexpected Drug Acting Through Unexpected Pathways

The research team tested brigatinib, an FDA-approved treatment for certain lung cancers, as a potential way to block the early survival response. Brigatinib was selected because it inhibits multiple signaling pathways involved in cancer cell survival - a broader pharmacological profile than more targeted agents.

In preclinical models, combining brigatinib with a PARP inhibitor outperformed either drug alone. This benefit appeared specifically in cancer cells rather than normal cells, suggesting a potentially favorable safety profile. But the mechanism behind brigatinib's benefit was not what the team anticipated.

Rather than acting through DNA repair pathways - the conventional target in PARP inhibitor combination strategies - brigatinib was found to simultaneously inhibit two signaling molecules called FAK and EPHA2. These molecules help aggressive ovarian cancer cells sustain themselves under treatment stress. By blocking both at once, the drug weakened the cells' adaptive capacity, leaving them more vulnerable to the PARP inhibitor's effects.

This dual-pathway inhibition may matter. Previous attempts to overcome PARP inhibitor resistance by targeting a single pathway have repeatedly encountered limits. Disrupting two convergent survival signals simultaneously is a different approach with a different theoretical basis.

A Potential Biomarker for Patient Selection

One of the more practically significant aspects of the study involves patient selection. Tumors with higher levels of FAK and EPHA2 responded better to the drug combination in preclinical models. Other data indicate that ovarian cancers with elevated levels of these molecules tend to be more aggressive - which means the approach may offer the greatest potential benefit precisely in the cases that are hardest to treat.

If this biomarker relationship holds in clinical testing, it could help identify which patients are most likely to benefit from brigatinib combined with PARP inhibitors, rather than applying the combination broadly where it may offer little additional benefit.

Where the Research Stands

This is preclinical work - conducted in cancer cell lines and animal models. The results have not been tested in patients. Safety, effective doses, optimal schedules, and which patient populations benefit most are all questions that clinical trials would need to address. The FRA1 pathway and the FAK/EPHA2 mechanism identified here provide testable hypotheses for that next stage of development.

"From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer," said John Weroha, medical oncologist at Mayo Clinic and senior author of the study. "By combining mechanistic insights from the laboratory with clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold."